2025年泽尼达妥单抗最新价格是多少钱一盒？

Zenidatuzumab is the world's first bispecific antibody therapy for HER2-positive biliary tract cancer. Its price, launch status and drug preparation are the focus of attention of patients and medical workers. In 2025, the drug will be priced at US$13,372 per box (300mg*2 bottles) in the US market and has not yet been launched in China. This article will detail its price information, global launch progress and preparations before use.

How much is the latest price of a box of zenidatuzumab in 2025

As an innovative biological agent, the price of zenidatuzumab reflects the research and development costs and clinical value. Understanding drug pricing is of great significance to patient treatment planning.

US market pricing

The price of zenidatuzumab in the US market in 2025 is US$13,372/box, and the specification is 300mg*2 bottles/box. This price is set by the American Jazz Company and falls within the typical pricing range of innovative oncology drugs.

Factors affecting price

Drug pricing takes into account factors such as R&D investment, production process complexity and clinical benefits. As the world's first targeted therapy for HER2-positive biliary tract cancer, its pricing reflects its breakthrough therapeutic value.

Future price trends

As more countries approve marketing and potential generic drugs emerge, prices may gradually decrease. However, there is currently no clear price reduction plan, and patients need to make cost plans.

The high pricing of zenidatuzumab reflects its innovative value, and patients can reduce their financial burden through insurance coverage or assistance programs.

Global marketing status of Zenidatuzumab

The global marketing process of Zenidatuzumab directly affects the accessibility of the drug to patients in various regions, and understanding its approval status is crucial for treatment selection.

US listing status

It has been approved by the FDA for the treatment of HER2-positive biliary tract cancer, becoming the first targeted therapy for this indication.

China marketing progress

Currently, it has not been approved for marketing in China, nor has it been included in the medical insurance catalog. Domestic patients are temporarily unable to obtain the drug through formal channels.

Status of other regions

Regions such as Europe and Japan are under review, and some countries can apply for use through special channels.

The global launch of zenidatuzumab is still progressing, and patients should pay attention to the approval developments in their regions.

Pharmaceutical preparation of zenidatumab

Zenidatumab, as an intravenous infusion drug, requires strict pre-medication preparation and monitoring procedures. Standardized operations can improve the safety of treatment.

Patient screening criteria

HER2-positive (IHC3+) status needs to be confirmed by an FDA-approved test. Applicable only to patients who have progressed after prior gemcitabine-containing chemotherapy.

Pretreatment requirements

Prophylactic use of acetaminophen, antihistamines and corticosteroids is required 30-60 minutes before each dose to reduce the risk of infusion reactions.

Infusion Precautions

The first infusion takes 120-150 minutes, and subsequent infusions can be shortened to 60-90 minutes. A 0.2 micron filter is required and the infusion reaction is strictly monitored.

Patients should prepare medication in a standardized manner under the guidance of a doctor, and the medical team must strictly implement the operating procedures.